As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
Torge Rempe, MD
Advertisement
Assistant Professor of Neurology, University of Florida
Articles by Torge Rempe, MD
Advertisement
Latest Updated Articles
The State of Biomarkers in Multiple SclerosisPublished: November 27th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NRLP3 Inhibitor VTX3232 Well-Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
2
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
3
Rethinking Progressive MS Studies to Better Include Advanced Patients: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
4
Targeting CD19+ B Cells With Inebilizumab in Myasthenia Gravis
5
